Episodes (Page 2)
✨
Trispecific antibody tilrekimig targets IL-4, IL-13, and TSLP.
✨
Analysis of PREDMETH trial examined predictors of response to prednisone or methotrexate.
Vivienne Kahlmann
✨
"Normal" ferritin ranges can mask iron deficiency, according to ASH guideline panel.
✨
ASH guidelines recommend higher ferritin thresholds to detect iron deficiency.
✨
Exacerbation phenotype guides decisions on switching biologics for severe asthma.
✨
Study links childhood penicillin rash to later autoimmune disease risk.
Eyal Kristal
✨
Aortic disease care is advancing with new guidelines and trials.
✨
Hypoglycemia remains a significant risk for type 1 diabetes patients.
✨
Zasocitinib shows promise for clear skin in plaque psoriasis.
Linda Stein Gold
✨
Severe asthma patients still experience exacerbations on biologics.
✨
Enlicitide, an oral PCSK9 inhibitor, is approved for hypercholesterolemia.
✨
FDA updates sotatercept label for pulmonary arterial hypertension.
✨
Ritlecitinib stabilizes vitiligo, offering meaningful outcomes.
✨
Oral icotrokinra shows sustained psoriasis clearance over 112 weeks.
Andrew Blauvelt
Linda Stein Gold
✨
Denifanstat maintains acne control for 52 weeks.
✨
Risankizumab maintains high skin clearance rates for psoriasis.
Christopher G. Bunick
✨
Ritlecitinib shows promise for non-segmental vitiligo based on late-breaking data.
✨
Oral treatments are still needed for atopic dermatitis, especially in children.
Leon Kircik
✨
World Oxygen Day highlights gaps in oxygen therapy access and delivery.
✨
Dupilumab pregnancy registry shows no increased birth defect risk.
Tina Chambers